Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Inflammatory bowel disease (IBD) |
- Oral
-
1 month
up to
18 years
-
1
- 1.5
mg/kg/day
in 1
dose
|
| Oncological conditions |
- Oral
-
0 years
up to
18 years
Achtung: Dosis und Dosisfrequenz von Zytostatika hängen von der Erkrankung ab und sind stark neuen Erkenntnissen unterworfen. Zytostatika werden in der Onkologie/Hämatologie oftmals in Kombination verwendet. Aus diesem Grunde wird auf die detaillierten Behandlungsprotokolle verwiesen.
Als Hinweis wird folgende Dosierung des Herstellers angeführt: 2,5 mg/kg/Tag oder 50-75 mg/m2/Tag
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Hypoglycaemia (especially with low BMI or children <6 years).
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANTIMETABOLITES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Purine analogues |
|
|
|
L01BB06
|
|
|
|
L01BB05
|
|
|
|
L01BB07
|
|
|
|
L01BB03
|
| Pyrimidine analogues |
|
|
|
L01BC01
|
|
|
|
L01BC52
|
|
|
|
L01BC05
|
References
-
Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
-
Turner D, et al., Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN Evidence-Based Consensus Guidelines, JPGN, 2012, 55(3), 340-61
-
GlaxoSmithKline BV, SPC Puri-Nethol (RVG 00589) 13-2-2019, www.cbg-meb.nl
-
Nova, SmPC Xaluprine 20mg/ml Suspension zum Einnehmen (EU/1/11/727/001), 07/2017
-
MEDICE, SmPC Mercaptopurin 10mg Tabletten (64742.00.00), 10/2017
-
Aspen, SmPC Puri-Nethol 50mg Tabletten (6102083.00.00), 09/2017
-
Informatorium Medicamentorum., (Interacties), Geraadpleegd 16 aug 2018
-
Nova, SmPC Xaluprine 20mg/ml Suspension zum Einnehmen (EU/1/11/727/001), 07/2017
-
Wine E. et al., Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation, JPGN, 2025, 81(3), 765-815
Therapeutic Drug Monitoring
Overdose